SCHEMBL959671

SCHEMBL959671

CN(CCCc1cc(Nc2n[nH]c3ncccc23)nc(-c2ccccc2C(F)(F)F)n1)CCN1CCOCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.45
CYP2D6 P10635 8/20 0.45
CYP3A4 P08684 7/20 0.45
USP2 O75604 3/20 0.45
CYP2C19 P33261 5/20 0.45
ALOX15 P16050 3/20 0.45
HIF1A Q16665 3/20 0.45
HSD17B10 Q99714 3/20 0.45
CYP2C9 P11712 1/20 0.45
ALDH1A1 P00352 2/20 0.40
USP1 O94782 2/20 0.39
WDR48 Q8TAF3 2/20 0.39
GRM4 Q14833 2/20 0.38
TSHR P16473 3/20 0.37
CLK4 Q9HAZ1 3/20 0.37
TRPV1 Q8NER1 2/20 0.37
LMNA P02545 1/20 0.36
PIP4K2C Q8TBX8 1/20 0.36
LCK P06239 1/20 0.35
KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL957461 0.92 CYP1A2 (0.50) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL960717 0.88 CYP1A2 (0.51) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL959012 0.87 CYP1A2 (0.41) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL14622281 0.86 CYP1A2 (0.43) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL957594 0.85 PIP4K2C (0.42) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL959323 0.84 ACP1 (0.45) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL960712 0.83 CYP1A2 (0.40) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL962173 0.82 PIP4K2C (0.41) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL958515 0.81 PIP4K2C (0.40) CYP1A2CYP2D6CYP3A4USP2CYP2C19
SCHEMBL12946315 0.81 SMN1; SMN2 (0.40) CYP1A2CYP2D6CYP3A4USP2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872129-B2 Compositions useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
US-7872129-B2 Compositions useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
US-7872129-B2 Compositions useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
US-20090118278-A1 COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-07 US disclosed
US-20090118278-A1 COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-07 US disclosed
US-7491730-B2 Compositions useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-02-17 US disclosed
US-7491730-B2 Compositions useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118278-A1 COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 GSK3B, GSK3A, GSKIP CYP1A2 3247/4885CYP2D6 3036/4885CYP3A4 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.